BioNotebook: Blend raises VC cash; Actavis gets quick Namenda appeal; and three new deals
This article was originally published in Scrip
Executive Summary
Blend Therapeutics added $21m in equity and debt financing to its Series B venture capital round to advance the Watertown, Massachusetts-based company's Pentarin platform for the development of biologic-drug conjugates encapsulated in nanoparticles.